Chebulinic acid-enriched fraction ameliorates benign prostatic hyperplasia in Sprague-Dawley rats
Abstract
Benign prostatic hyperplasia (BPH) is a common problem among elderly men, characterized by neoplastic, non-malignant enlargement of the prostate, which causes its dysfunction and decreased urinary flow rate. At present, the primary medications available for managing BPH include alpha-blockers and 5-alpha-reductase inhibitors. However, these medications are usually steroids and often lead to adverse side effects. In contrast, natural therapeutic agents generally have minimal side effects, making phytomedicines promising alternatives. The present study demonstrated the therapeutic potential of chebulinic acid-enriched fraction (CAEF), extracted from
Terminalia chebula
fruits, for the management of BPH in the rat model. To develop this model, orchiectomy was done on Sprague–Dawley male rats, which were allowed to recover for 10 days after surgery. Subcutaneous injections of testosterone (5 mg/kg) were administered daily for 7 days to induce a BPH rat model. From the 8
th
day onward, after the first testosterone injection, CAEF was administered through the oral route (100 mg/kg of body weight) to the BPH-induced group, while vehicle-operated rats served as controls. After 4, 8, and 12 weeks of treatment, the animals were sacrificed, where a significant reduction in the prostate index was observed. Histological observations of the prostate showed reduced epithelial thickness in the treated animals, comparable to the healthy control group. Furthermore, the most important indicator…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.